MOORESVILLE, N.C., Jan. 18, 2021 /PRNewswire/ -- Biohaven
Pharmaceuticals (NYSE:BHVN) announced today that Cody Ware will pilot the Nurtec® ODT
(rimegepant) #51 Chevrolet Camaro for Rick Ware Racing during the
2021 NASCAR Cup Series season. The first race of the season with
Cody behind the wheel is the DAYTONA 500, at Daytona International
Speedway on February 14.
Cody Ware commented, "I am pumped
to head to Daytona International Speedway with Biohaven as our
primary sponsor. As a person with migraine, it's even more
meaningful for me to drive the Nurtec ODT #51 car to raise
awareness of this debilitating disease, especially at the biggest
race of the year. We have a lot of exciting things planned for
2021, and I look forward to competing in the NASCAR Cup Series
again."
A veteran of 51 starts across the top three NASCAR series, Cody
has highlights of a 7th place finish at the
Charlotte Roval in the Xfinity series and a
19th place finish at Talladega in the NASCAR Cup
series. Cody's career accolades also include the 2020 Asian Le Mans
series championship along with 2014 Lamborghini Super Trofeo North
America Rookie of the Year.
Vlad Coric, MD, Chief Executive
Officer of Biohaven stated, "We are very excited that Cody will be
driving the Nurtec ODT car at the NASCAR races and to be working
with him to raise awareness about migraine and Nurtec ODT. As a
person with migraine and someone who has to deal with so many
migraine triggers on the racetrack, Cody will help elevate the
conversation about the importance of an effective acute
treatment for migraine."
Nearly 40 million people in the U.S. suffer from migraine
and the World Health Organization classifies migraine as one of the
10 most disabling medical illnesses. Migraine is
characterized by debilitating attacks lasting four to 72 hours with
multiple symptoms, including pulsating headaches of moderate to
severe pain intensity that can be associated with nausea or
vomiting, and/or sensitivity to sound (phonophobia) and sensitivity
to light (photophobia).
Nurtec ODT was approved by the U.S. Food and Drug
Administration (FDA) for the acute treatment of migraine in
February 2020 and is the first and
only CGRP receptor antagonist available in an orally disintegrating
tablet (ODT). A single dose of Nurtec ODT has been shown to get
people with migraine back to normal functioning within 60 minutes
and have lasting effects for up to 48 hours.
Rick Ware, former driver and
current team owner, said, "We are super excited to start the season
off at Daytona International Speedway, where we have had some
great runs in the past. This will be the first race as part of the
Nurtec ODT partnership, and we are hoping to have a successful day
on the track, and bring home a great finish for the team and
our sponsor."
For additional information on Nurtec ODT,
visit www.nurtec.com. Follow Rick Ware Racing, by
visiting www.wareracing.com, and be sure to follow along on
social media
(Facebook, Twitter and/or Instagram).
About Rick Ware Racing
With a rich and extensive history, Rick Ware Racing has been
part of the racing fabric in the USA for over 30 years. The team has recently
competed in both Prototypes and the NASCAR Cup Series. The team
most recently claimed the 2020 Asian Le Mans Series Am
Championship.
About Biohaven
Biohaven is a commercial-stage biopharmaceutical company with a
portfolio of innovative, best-in-class therapies to improve the
lives of patients with debilitating neurological and
neuropsychiatric diseases, including rare disorders. Biohaven's
neuroinnovation portfolio includes FDA-approved NURTEC®
ODT (rimegepant) for the acute treatment of migraine and a broad
pipeline of late-stage product candidates across three distinct
mechanistic platforms: CGRP receptor antagonism for the acute and
preventive treatment of migraine; glutamate modulation for
obsessive-compulsive disorder, Alzheimer's disease, and
spinocerebellar ataxia; and MPO inhibition for multiple system
atrophy and amyotrophic lateral sclerosis. More information about
Biohaven is available at www.biohavenpharma.com.
About NURTEC ODT
NURTEC® ODT (rimegepant) is the first and only
calcitonin gene-related peptide (CGRP) receptor antagonist
available in a quick-dissolve ODT formulation that is approved by
the U.S. Food and Drug Administration (FDA) for the acute
treatment of migraine in adults. The activity of the neuropeptide
CGRP is thought to play a causal role in migraine pathophysiology.
NURTEC ODT is a CGRP receptor antagonist that works by reversibly
blocking CGRP receptors, thereby inhibiting the biologic activity
of the CGRP neuropeptide. The recommended dose of NURTEC ODT is 75
mg, taken as needed, up to once daily. For more information about
NURTEC ODT, visit www.nurtec.com.
Indication
NURTEC® ODT (rimegepant) is indicated for the acute
treatment of migraine with or without aura in adults.
Limitations of Use
NURTEC ODT is not indicated for the preventive treatment of
migraine.
Important Safety Information
Contraindications: Hypersensitivity to NURTEC ODT or
any of its components.
Warnings and Precautions: If a serious
hypersensitivity reaction occurs, discontinue NURTEC ODT and
initiate appropriate therapy. Serious hypersensitivity
reactions have included dyspnea and rash, and can occur days after
administration.
Adverse Reactions: The most common adverse reaction
was nausea (2% in patients who received NURTEC ODT compared to 0.4%
in patients who received placebo). Hypersensitivity, including
dyspnea and rash, occurred in less than 1% of patients treated with
NURTEC ODT.
Drug Interactions: Avoid concomitant administration
of NURTEC ODT with strong inhibitors of CYP3A4, strong or moderate
inducers of CYP3A or inhibitors of P-gp or BCRP. Avoid another dose
of NURTEC ODT within 48 hours when it is administered with moderate
inhibitors of CYP3A4.
Use in Specific Populations:
Pregnant/breast feeding: It is not known if NURTEC ODT can harm an
unborn baby or if it passes into breast milk.
Hepatic impairment: Avoid use of NURTEC ODT in persons with severe
hepatic impairment.
Renal impairment: Avoid use in patients with end-stage renal
disease.
Please click here for full Prescribing
Information.
You are encouraged to report side effects of prescription
drugs to the FDA. Visit www.fda.gov/medwatch or
call 1-800-FDA-1088 or report side effects to Biohaven at
1-833-4Nurtec.
Please click here for full Prescribing
Information and Patient Information.
NURTEC is a trademark of Biohaven Pharmaceutical Ireland
DAC
Biohaven Contact:
Vlad Coric, M.D.
Chief Executive Officer
Vlad.Coric@biohavenpharma.com
Media Contact:
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
312-961-2502
Rick Ware Racing Contact:
Kate Fegley
Kate@K1Marketing.biz
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biohaven-signs-cody-ware-as-driver-for-nurtec-odt-chevrolet-for-the-2021-nascar-cup-series-season-301210092.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.